The goal of the SPORE in Pancreatic Cancer Developmental Research Program (DRP) is to recruit and support developmental research projects in pancreatic cancer, for future incorporation as full SPORE projects or as the basis for applications for other major peer-review funding. The types of research projects to be supported basic research, clinical research, epidemiologic studies, and cancer prevention and control in pancreatic cancer. Projects will expand the scope of translational research and increase the number of investigators committed to pancreatic cancer research. This program is open to all of the institutions participating in the SPORE, and any of their collaborators. In addition, plans call for development of new projects with other SPOREs. This program, along with the Career Enhancement Program, is consistent with the Siteman Cancer Center's overall commitment to the recruitment of minority and underrepresented investigators. New research projects are solicited and funded through developmental funds. In this application, two to three developmental projects will be funded each year throughout the life of the SPORE. Requests for Applications (RFA) for developmental projects in pancreatic cancer research will be requested annually. All developmental project applications will be reviewed by a Research Development Advisory Committee consisting of scientists (representing basic and applied science) with expertise in pancreatic cancer, a biostatistician, a patient advocate, and ad hoc members, as necessary (special expertise, no conflict of interest). This committee will make recommendations to the Pancreatic Cancer SPORE Steering Committee, which will make final funding decisions.

Public Health Relevance

The work proposed will lead to an improved understanding of pancreatic cancer biology and will lead to new approaches in early detection, prevention, imaging and treatment for this refractory malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196510-02
Application #
9321895
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Pati, Maria Laura; Niso, Mauro; Spitzer, Dirk et al. (2018) Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (?2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. Eur J Med Chem 144:359-371
Brauer, David G; Ohman, Kerri A; Jaques, David P et al. (2018) Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes? J Am Coll Surg 226:37-45.e1
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Nywening, Timothy M; Belt, Brian A; Cullinan, Darren R et al. (2018) Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112-1123
Brenot, Audrey; Knolhoff, Brett L; DeNardo, David G et al. (2018) SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion. Oncogenesis 7:32
Meyer, Melissa A; Baer, John M; Knolhoff, Brett L et al. (2018) Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun 9:1250
Meyer, Melissa A; DeNardo, David G (2018) Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. Immunity 48:621-623
Jiang, Hongmei; Xu, Mai; Li, Lin et al. (2018) Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Mol Cancer Ther 17:2144-2155
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Zhang, Daoxiang; Li, Lin; Jiang, Hongmei et al. (2018) Tumor-Stroma IL1?-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Res 78:1700-1712

Showing the most recent 10 out of 25 publications